Ironwood Pharmaceuticals (IRWD) Cash & Current Investments (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Cash & Current Investments for 17 consecutive years, with $184.3 million as the latest value for Q4 2025.
- Quarterly Cash & Current Investments rose 108.11% to $184.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $184.3 million through Dec 2025, up 108.11% year-over-year, with the annual reading at $184.3 million for FY2025, 108.11% up from the prior year.
- Cash & Current Investments hit $184.3 million in Q4 2025 for Ironwood Pharmaceuticals, up from $140.4 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $741.6 million in Q1 2023 to a low of $88.2 million in Q3 2024.
- Historically, Cash & Current Investments has averaged $325.8 million across 5 years, with a median of $180.2 million in 2023.
- Biggest five-year swings in Cash & Current Investments: plummeted 85.98% in 2023 and later soared 108.11% in 2025.
- Year by year, Cash & Current Investments stood at $621.4 million in 2021, then rose by 5.81% to $657.5 million in 2022, then tumbled by 85.98% to $92.2 million in 2023, then fell by 3.9% to $88.6 million in 2024, then skyrocketed by 108.11% to $184.3 million in 2025.
- Business Quant data shows Cash & Current Investments for IRWD at $184.3 million in Q4 2025, $140.4 million in Q3 2025, and $92.9 million in Q2 2025.